College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065, USA.
J Pharm Pharm Sci. 2012;15(3):433-46. doi: 10.18433/j36k6z.
To determine the correlations/discrepancies of drug stabilities between in the homogenates of human culture cells and of human tissues.
Amino acid/dipeptide monoester prodrugs of floxuridine were chosen as the model drugs. The stabilities (half-lives) of floxuridine prodrugs in human tissues (pancreas, liver, and small intestine) homogenates were obtained and compared with ones in cell culture homogenates (AcPC-1, Capan-2, and Caco-2 cells) as well as human liver microsomes. The correlations of prodrug stability in human small bowel tissue homogenate vs. Caco-2 cell homogenate, human liver tissue homogenate vs. human liver microsomes, and human pancreatic tissue homogenate vs. pancreatic cell, AsPC-1 and Capan-2, homogenates were examined.
The stabilities of floxuridine prodrugs in human small bowel homogenate exhibited the great correlation to ones in Caco-2 cell homogenate (slope = 1.0-1.3, r2 = 0.79-0.98). The stability of those prodrugs in human pancreas tissue homogenate also exhibited the good correlations to ones in AsPC-1 and Capan-2 cells homogenates (slope = 0.5-0.8, r2 = 0.58-0.79). However, the correlations of prodrug stabilities between in human liver tissue homogenates and in human liver microsomes were weaker than others (slope = 1.3-1.9, r2 = 0.07-0.24).
The correlations of drug stabilities in cultured cell homogenates and in human tissue homogenates were compared. Those results exhibited wide range of correlations between in cell homogenate and in human tissue homogenate (r2 = 0.07 - 0.98). Those in vitro studies in cell homogenates would be good tools to predict drug stabilities in vivo and to select drug candidates for further developments. In the series of experiments, 5'-O-D-valyl-floxuridine and 5'-O-L-phenylalanyl-L-tyrosyl-floxuridine would be selected as candidates of oral drug targeting delivery for cancer chemotherapy due to their relatively good stabilities compared to other tested prodrugs.
确定人细胞和人组织匀浆中药物稳定性的相关性/差异。
选择氟尿苷的氨基酸/二肽单酯前药作为模型药物。获得氟尿苷前药在人组织(胰腺、肝脏和小肠)匀浆中的稳定性(半衰期),并将其与细胞培养物匀浆(AcPC-1、Capan-2 和 Caco-2 细胞)以及人肝微粒体中的稳定性进行比较。检查了人小肠组织匀浆中前药稳定性与 Caco-2 细胞匀浆、人肝组织匀浆与人肝微粒体以及人胰腺组织匀浆与胰腺细胞(AsPC-1 和 Capan-2)匀浆之间的相关性。
氟尿苷前药在人小肠匀浆中的稳定性与 Caco-2 细胞匀浆中的稳定性具有很大的相关性(斜率=1.0-1.3,r2=0.79-0.98)。这些前药在人胰腺组织匀浆中的稳定性也与人胰腺细胞 AsPC-1 和 Capan-2 匀浆中的稳定性呈良好相关性(斜率=0.5-0.8,r2=0.58-0.79)。然而,前药稳定性在人肝组织匀浆与肝微粒体之间的相关性弱于其他(斜率=1.3-1.9,r2=0.07-0.24)。
比较了培养细胞匀浆和人组织匀浆中药物稳定性的相关性。结果表明,细胞匀浆与人体组织匀浆之间的相关性范围很广(r2=0.07-0.98)。细胞匀浆的这些体外研究将是预测体内药物稳定性和选择进一步开发的候选药物的良好工具。在一系列实验中,由于与其他测试前药相比具有相对较好的稳定性,5'-O-D-缬氨酸-氟尿苷和 5'-O-L-苯丙氨酸-L-酪氨酸-氟尿苷将被选为癌症化疗口服靶向药物输送的候选药物。